Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0000902664-26-000024·Matrix Capital Management Company, LP
Schedule 13D ownership disclosure
Zentalis Pharmaceuticals, Inc.
Common Stock, par value $0.001 per share · CUSIP: 98943L107
Event date: 2025-12-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Matrix Capital Management Company, LPReported CIK 0001410830
Shares: 0.00 · Class: 0%
- David E. GoelReported CIK 0001548144
Shares: 0.00 · Class: 0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000902664-26-000024
- Form type
- SCHEDULE 13D/A
- Filer
- Matrix Capital Management Company, LP
- CIK
- CIK 1410830
- Filed
- Jan 02, 2026
- Reporting period
- Dec 30, 2025
- Description
- Schedule 13D beneficial ownership